This research study is evaluating a drug called clofarabine as a possible treatment for Langerhans Cell Histiocytosis (LCH) and and other histiocytic disorders.
Name: ClofarabineDescription: Evaluation of response to clofarabineType: Drug
1-Recurrent or Refractory LCH 2-LCH-related disorders
Description: Responses will be assessed using the standard criteria proposed by the Histiocyte SocietyMeasure: Overall Response Rate Time: Week 7
Single Group Assignment
There is one SNP
ECD patients who have confirmed BRAF V600E mutation must have failed treatment with a BRAF inhibitor or are not considered to be eligible for such treatment. --- V600E ---